Attachment

NIH-Funded ACTIV/ACTIV-Associated Clinical Trials I National Institutes of Health (NIH) B® nih.gow/activinin-funded-activ/activ-associated-clinical-trials NIH) National Institutes of Health Turning Discovery Into Health Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) February 11, 2021 New/ Estimated Company Therapeutic Class Administration Repurposed End Date ACTIV-1 Inpatient BMS Orencia Immune Intravenous Repurposed 4 2021 (abatacept) Modulator Janssen Remicade Immune Intravenous Repurposed Q4 2021 (Infliximab) Modulator AbbVie Cenicriviroc Immune Oral New Q4 2021 Modulator ACTIV-2 Outpatient AstraZeneca AZD7442 Monoclonal Intramuscular New Q4 2021 Antibody Cocktail AstraZeneca AZD7442 Monoclonal Intravenous New Q4 2021 Antibody Cocktail Brii Biosciences Brii-196 & Brii- Monoclonal Intravenous New Q4 2021 Antibody Cocktail Eli Lilly LY-CoV-555 Monoclonal Intravenous New Q1 2021 Antibody Single Sagent Camostat Antiviral Oral Repurposed Mesylate Synairgen SNGO01 IFN- Immune Inhaled Repurposed 4 2021 beta Modulator ACTIV-3 Inpatient 1/3